{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:33:14Z","timestamp":1707525194000},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,5]]},"DOI":"10.7759\/cureus.41394","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T10:45:10Z","timestamp":1688553910000},"source":"Crossref","is-referenced-by-count":0,"title":["Seronegative Rheumatoid Arthritis Secondary to Immune Checkpoint Inhibitor in a Renal Cell Carcinoma Patient Encountered in a Rural Community-Based Rheumatology Clinic: A Case Report"],"prefix":"10.7759","author":[{"given":"Elmer R","family":"De Camps Martinez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamzah","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hafsa","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farooq","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma. (2018). Accessed. April 16, 2018: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-plus-ipilimumab-combination-int...."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0390","article-title":"Inflammatory arthritis: a newly recognized adverse event of immune checkpoint blockade","volume":"22","author":"Naidoo J","year":"2017","unstructured":"Naidoo J, Cappelli LC, Forde PM, et al.. Inflammatory arthritis: a newly recognized adverse event of immune checkpoint blockade. Oncologist. 2017, 22:627-30. 10.1634\/theoncologist.2016-0390","journal-title":"Oncologist"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals M","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK, et al.. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020, 6:38. 10.1038\/s41572-020-0160-6","journal-title":"Nat Rev Dis Primers"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature","volume":"69","author":"Cappelli LC","year":"2017","unstructured":"Cappelli LC, Gutierrez AK, Bingham CO 3rd, Shah AA. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res (Hoboken). 2017, 69:1751-63. 10.1002\/acr.23177","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04665-7","article-title":"Immune checkpoint inhibitor-induced musculoskeletal manifestations","volume":"41","author":"Angelopoulou F","year":"2021","unstructured":"Angelopoulou F, Bogdanos D, Dimitroulas T, Sakkas L, Daoussis D. Immune checkpoint inhibitor-induced musculoskeletal manifestations. Rheumatol Int. 2021, 41:33-42. 10.1007\/s00296-020-04665-7","journal-title":"Rheumatol Int"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha D","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, et al.. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010, 62:2569-81. 10.1002\/art.27584","journal-title":"Arthritis Rheum"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider BJ","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021, 39:4073-126. 10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/iju5.12560","article-title":"Seronegative rheumatoid arthritis after combination therapy with ipilimumab and nivolumab for postoperative pancreatic and liver metastases from renal cell carcinoma","volume":"6","author":"Nishimura Y","year":"2023","unstructured":"Nishimura Y, Yamanaka K, Kato T, et al.. Seronegative rheumatoid arthritis after combination therapy with ipilimumab and nivolumab for postoperative pancreatic and liver metastases from renal cell carcinoma. IJU Case Rep. 2023, 6:101-5. 10.1002\/iju5.12560","journal-title":"IJU Case Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4103\/ajm.AJM_127_17","article-title":"Nivolumab-induced new-onset seronegative rheumatoid arthritis in a patient with advanced metastatic melanoma: a case report and literature review","volume":"8","author":"Haikal A","year":"2018","unstructured":"Haikal A, Borba E, Khaja T, Doolittle G, Schmidt P. Nivolumab-induced new-onset seronegative rheumatoid arthritis in a patient with advanced metastatic melanoma: a case report and literature review. Avicenna J Med. 2018, 8:34-6. 10.4103\/ajm.AJM_127_17","journal-title":"Avicenna J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/167546-seronegative-rheumatoid-arthritis-secondary-to-immune-checkpoint-inhibitor-in-a-renal-cell-carcinoma-patient-encountered-in-a-rural-community-based-rheumatology-clinic-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:02:50Z","timestamp":1707508970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/167546-seronegative-rheumatoid-arthritis-secondary-to-immune-checkpoint-inhibitor-in-a-renal-cell-carcinoma-patient-encountered-in-a-rural-community-based-rheumatology-clinic-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,5]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.41394","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,5]]}}}